Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia
- PMID: 24490025
- PMCID: PMC3896130
- DOI: 10.1177/2045125313499065
Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia
Abstract
Objective: To assess the cognitive effects of sertindole and olanzapine in patients diagnosed with schizophrenia. Cognition was the primary outcome of the study.
Method: This was a 12-week double-blinded randomized clinical controlled trial. Participants were randomized to either 16-24 mg of sertindole or 10-20 mg of olanzapine.
Results: The study had a low recruitment rate (N = 9) and was terminated before the expected number of patients was reached. No significant differences between groups were found at study end on any of the 32 cognitive subtests. A simple sign test did not show any of the comparator drugs trending towards being superior on the majority of tests. Mean change on Positive and Negative Syndrome Scale (PANSS) total and PANSS subscales from baseline to end of study were not significantly different between treatment groups. Similar results on cognition and PANSS was seen on completers and last observation carried forward analysis.
Conclusion: In this study we did not find any significant differences between sertindole or olanzapine on PANSS subscales or neurocognitive tests in a population consisting of patients diagnosed with schizophrenia.
Keywords: cognition; olanzapine; randomized controlled trial; schizophrenia; sertindole.
Conflict of interest statement
Figures
Similar articles
-
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.J Clin Psychiatry. 2007 Mar;68(3):368-79. doi: 10.4088/jcp.v68n0303. J Clin Psychiatry. 2007. PMID: 17388705 Clinical Trial.
-
The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.Int Clin Psychopharmacol. 2012 Nov;27(6):326-35. doi: 10.1097/YIC.0b013e32835767a0. Int Clin Psychopharmacol. 2012. PMID: 22850268 Clinical Trial.
-
Effects of sertindole on cognition in clozapine-treated schizophrenia patients.Acta Psychiatr Scand. 2012 Jul;126(1):31-9. doi: 10.1111/j.1600-0447.2012.01840.x. Epub 2012 Feb 22. Acta Psychiatr Scand. 2012. PMID: 22356584 Clinical Trial.
-
[Cognition, schizophrenia and the effect of antipsychotics].Encephale. 2006 May-Jun;32(3 Pt 1):341-50. doi: 10.1016/s0013-7006(06)76162-0. Encephale. 2006. PMID: 16840928 Review. French.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
Cited by
-
Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders".Front Behav Neurosci. 2015 Aug 12;9:210. doi: 10.3389/fnbeh.2015.00210. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26321931 Free PMC article. No abstract available.
-
Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis.JAMA Psychiatry. 2025 Jan 1;82(1):47-56. doi: 10.1001/jamapsychiatry.2024.2890. JAMA Psychiatry. 2025. PMID: 39412783
References
-
- Addington D., Addington J., Maticka-Tyndale E. (1994) Specificity of the Calgary Depression Scale for Schizophrenics. Schizophr Res 11: 239–244 - PubMed
-
- Addington D., Addington J., Maticka-Tyndale E., Joyce J. (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6: 201–208 - PubMed
-
- Buchanan R., Davis M., Goff D., Green M., Keefe R., Leon A., et al. (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31: 5–19 - PubMed
-
- Cannon T., Zorrilla L., Shtasel D., Gur R., Gur R., Marco E., et al. (1994) Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 51: 651–661 - PubMed
-
- Caspi A., Reichenberg A., Weiser M., Rabinowitz J., Kaplan Z., Knobler H., et al. (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 65: 87–94 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources